Company News: Humabs BioMed Reports Clinical Milestone in Antibody Licensing Agreement
Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that it has received a milestone payment from its licensing agreement with Novartis. In 2009, Humabs and Novartis entered into an exclusive licensing agreement for the use of selective human monoclonal antibodies discovered by Humabs’ proprietary Cellclone technology. A Novartis program based on this technology has entered into phase II clinical trials in the U.S. and Germany, triggering the payment.
“We are very pleased about reaching this important milestone,” said Alcide Barberis, CEO of Humabs BioMed. “This underlines the value of our platform, which is not just selecting for binders to pre-defined targets, but uses a functional, target-agnostic approach.”
Company News: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015